Gland Pharma Ltd

Integrated Filing — Corporate Governance (NSE XBRL)

Company Home Dashboard NSE Viewer

Filing Summary

Company
Gland Pharma Limited
Symbol
GLAND
Quarter Ended
31-Mar-2026
Submission
Revision
Revision Remarks
Risk Management Committee Meeting held on January 28, 2026 was inadvertently missed out in the Original filing

General Disclosures

Advertisements As Per Regulation471
Yes
Annual Return As Provided Under Section92Of The Companies Act2013
Yes
Approval For Material Related Party Transactions
Not Applicable
Approval Of The Board And Shareholders For Compensation Or Profit Sharing
Not Applicable
Audio Or Video Recordings And Transcripts Of Post Earinings Or Quarterly Calls
Yes
Board Composition
Yes
Code Of Conduct
Yes
Compliance Certificate
Yes
Compliance With Sub Regulation3Of Regulation46With Respect To Accuracy Of Disclosures On The Website And Timely Updation
Yes
Confirmation That The Disclosures Are In A Separate Section As Specified In Sub Regulation2Of Regulation46
Yes
Credit Rating Or Revision In Credit Rating Obtained
Not Applicable
Date Of End Of Financial Year
31-Mar-2026
Date Of End Of Reporting Period
31-Mar-2026
Date Of Signing
13-May-2026
Date Of Start Of Financial Year
01-Apr-2025
Designation Of Person
Company Secretary and Compliance Officer
Designation Of Person Affirmations
Company Secretary and Compliance Officer
Designation Of Person For Annual Affirmations
Company Secretary and Compliance Officer
Designation Of Person For Quartely Affirmations
Company Secretary and Compliance Officer
Details Of Agreements Entered Into With The Media Companies And Or Their Associates
Not Applicable
Details Of Business
Yes
Details Of Establishment Of Vigil Mechanism Or Whistle Blower Policy
Yes
Disclosure Of Contact Details Of KMP Who Are Authorized For The Purpose Of Determining Materiality Under Sub Regulation5Of Regulation30
Yes
Disclosure Of Related Party Transactions On Consolidated Basis
Yes
Disclosure Web Link Of Annual Return As Provided Under Section92Of The Companies Act2013Is Placed
https://glandpharma.com/investors/annual-return
Disclosure Web Link Of Audio Or Video Recordings And Transcripts Of Post Earinings Or Quarterly Calls Is Placed
https://glandpharma.com/investors/financials
Disclosure Web Link Of Company At Advertisements As Per Regulation471Is Placed
https://glandpharma.com/investors/stock-exchange-anouncement#newspaper_publication
Disclosure Web Link Of Company At Dividend Distribution Policy As Per Regulation43A1Is Placed
https://glandpharma.com/images/Dividend_distribution_policy.pdf
Disclosure Web Link Of Company At Materiality Policy As Per Sub Regulation4Regulation30Is Placed
https://glandpharma.com/images/Policy_for_determination.pdf
Disclosure Web Link Of Company At Separate Audited Financial Statements Of Each Subsidiary Of The Listed Entity Is Placed
https://glandpharma.com/investors/subsidiary-financials
Disclosure Web Link Of Company At Which Details Of Business Is Placed
https://glandpharma.com/our-business/business-model
Disclosure Web Link Of Company At Which Details Of Establishment Of Vigil Mechanism Or Whistle Blower Policy Is Placed
https://glandpharma.com/images/whistle_blower_policy.pdf
Disclosure Web Link Of Company At Which Financial Results Is Placed
https://glandpharma.com/investors/financials
Disclosure Web Link Of Company At Which Policy For Determining Material Subsidiaries Is Placed
https://glandpharma.com/images/Policy_for_determining_Material_Subsidiaries.pdf
Disclosure Web Link Of Company At Which Policy On Dealing With Related Party Transactions Is Placed
https://glandpharma.com/images/Policy_of_Related_Party_Transactions.pdf
Disclosure Web Link Of Company At Which Shareholding Pattern Is Placed
https://glandpharma.com/investors/shareholder-information#shareholding-pattern
Disclosure Web Link Of Compliance With Sub Regulation3Of Regulation46With Respect To Accuracy Of Disclosures On The Website And Timely Updation Is Placed
https://glandpharma.com/investors/disclosures-under-regulation-46-lodr
Disclosure Web Link Of Confirmation That The Disclosures Are In A Separate Section As Specified In Sub Regulation2Of Regulation46Is Placed
https://glandpharma.com/investors/disclosures-under-regulation-46-lodr
Disclosure Web Link Of Disclosure Of Contact Details Of KMP Who Are Authorized For The Purpose Of Determining Materiality Under Sub Regulation5Of Regulation30Is Placed
https://glandpharma.com/images/Policy_for_determination.pdf
Disclosure Web Link Of Disclosures Under Sub Regulation8Of Regulation30Is Placed
https://glandpharma.com/investors/stock-exchange-anouncement#other_announcements
Disclosure Web Link Of Employee Benefit Scheme Documents Framed In Terms Of SEBI Share Based Employee Benefits And Sweat Equity Regulations2021Is Placed
https://glandpharma.com/investors/shareholder-information#employeeBenefitScheme
Disclosure Web Link Of Memorandum Of Association And Articles Of Association Is Placed
https://glandpharma.com/images/Gland_Pharma-MOA-and-AOA-2020.pdf
Disclosure Web Link Of Schedule Of Analyst Or Institutional Investor Meet And Presentation Prepared By Listed Entity For Analyst Or Institutional Investor Meet Is Placed
i. https://glandpharma.com/investors/stock-exchange-anouncement#analyst_meetings ii. https://glandpharma.com/investors/presentation
Disclosure Web Link Of Secretarial Compliance Report Is Placed
https://glandpharma.com/investors/shareholder-information#annual-secretarial-compliance-report
Disclosures Under Sub Regulation8Of Regulation30
Yes
Dividend Distribution Policy As Per Regulation43A1
Yes
Employee Benefit Scheme Documents Framed In Terms Of SEBI Share Based Employee Benefits And Sweat Equity Regulations2021
Yes
Fees Or Compensation
Yes
Financial Results
Yes
Is SCORESID Available
Yes
ISIN
INE068V01023
Market Capitalisation As Per Immediate Previous Financial Year
Top 500 listed entities
Materiality Policy As Per Sub Regulation4Regulation30
Yes
Memorandum Of Association And Articles Of Association
Yes
Minimum Information
Yes
MSEI Symbol
NOTLISTED
Name Of Signatory
Sampath Kumar Pallerlamudi
Name Of Signatory Affirmations
Sampath Kumar Pallerlamudi
Name Of Signatory For Annual Affirmations
Sampath Kumar Pallerlamudi
Name Of Signatory For Quartely Affirmations
Sampath Kumar Pallerlamudi
Name Of The Company
GLAND PHARMA LIMITED
New Name And The Old Name Of The Listed Entity
Not Applicable
Other Corporate Governance Requirements With Respect To Subsidiary Of Listed Entity
Yes
Place
Hyderabad
Plans For Orderly Succession For Appointments
Yes
Policy For Determining Material Subsidiaries
Yes
Policy For Related Party Transaction
Yes
Policy On Dealing With Related Party Transactions
Yes
Reason For Part F Of Annexure I Of The SEBI Circular Dated31December2024Related To Disclosure Of Loans Or Guarantees Or Comfort Letters Or Securities Etc Is Not Applicable To The Entity
Not applicable during this quarter
Recommendation Of Board
Yes
Reporting Quarter
Yearly
Review Of Compliance Reports
Yes
Risk Assessment And Management
Yes
Schedule Of Analyst Or Institutional Investor Meet And Presentation Prepared By Listed Entity For Analyst Or Institutional Investor Meet
Yes
SCORES Registration ID
COMZ00813
Scrip Code
543245
Secretarial Compliance Report
Yes
Separate Audited Financial Statements Of Each Subsidiary Of The Listed Entity
Yes
Shareholding Pattern
Yes
Statements Of Deviations Or Variations As Specified In Regulation32
Not Applicable
Symbol
GLAND
The Listed Entity Has Approved Material Subsidiary Policy And The Corporate Governance Requirements With Respect To Subsidiary Of Listed Entity Have Been Complied
Yes
Type Of Company
Equity
Type Of Submission
Revision
Vacancies In Respect Key Managerial Personnel
Not Applicable
Vigil Mechanism
Yes
Whether As Per Sub Regulation2ba Of Regulation27Of SEBILODR There Has Been Cyber Security Incidents During The Quarter
No
Whether Part A Of Annexure I Of The SEBI Circular Dated31December2024Related To Compliance Report On Corporate Governance Is Applicable To The Entity
Yes
Whether Part F Of Annexure I Of The SEBI Circular Dated31December2024Related To Disclosure Of Loans Or Guarantees Or Comfort Letters Or Securities Etc Is Applicable To The Entity
No

Additional Disclosures

Entry D_MeetingBOD1
Whether Requirement Of Quorum Met
Yes
Entry D_MeetingBOD2
Whether Requirement Of Quorum Met
Yes
Entry D_MeetingComit1
Whether Requirement Of Quorum Met
Yes
Entry D_MeetingComit2
Whether Requirement Of Quorum Met
Yes
Entry D_MeetingComit3
Whether Requirement Of Quorum Met
Yes
Entry D_MeetingComit4
Whether Requirement Of Quorum Met
Yes
Entry D_MeetingComit5
Whether Requirement Of Quorum Met
Yes
Entry D_MeetingComit6
Whether Requirement Of Quorum Met
Yes
Entry D_MeetingComit7
Whether Requirement Of Quorum Met
Yes
Official NSE disclosure viewer

If the viewer does not load, use the NSE Viewer button above to open it in a new tab.

Board Composition — Entity Disclosures

The Composition Of Board Of Directors Is In Terms Of Sebi Regulations2015
Yes
Chairperson Related to MD / CEO
No
Regular Chairperson
Yes

Composition of Board of Directors

SrTitleDirectorPANDINCategory 1Category 2Date of BirthDisqualifiedStatusSpecial ResolutionInitial AppointmentRe-appointmentTenure (months)Listed DirectorshipsIndependent DirectorshipsAudit / Stakeholder MembershipsAudit / Stakeholder Chair Posts
1MrSrinivas Sadu******06900659Executive DirectorChairperson15-Apr-1969NoActiveNot Applicable25-Apr-201925-Apr-20221010
2MrUDO JAHANNES VETTER******00707474Non-Executive - Independent DirectorNot Applicable23-Nov-1954NoActiveNot Applicable07-Feb-201821-Jul-2021561110
3MrEssaji Goolam Vahanvati******00157299Non-Executive - Independent DirectorNot Applicable01-Feb-1980NoActiveNot Applicable30-Sep-202030-Sep-2025662231
4MrSatyanarayana Murthy Chavali******00142138Non-Executive - Independent DirectorNot Applicable12-Mar-1967NoActiveNot Applicable20-Nov-201820-Nov-2023882243
5MsNaina Lal Kidwai******00017806Non-Executive - Independent DirectorNot Applicable16-Apr-1957NoActiveNot Applicable17-May-202117-May-2021583321
6MrJia Ai Zhang******09170927Non-Executive - Non Independent DirectorNot Applicable17-Apr-1961NoActiveNot Applicable17-May-20211000
7MrWenjie Zhang******10727581Non-Executive - Non Independent DirectorNot Applicable10-Feb-1967NoActiveNot Applicable30-Aug-20241010
8MsWei Huang******10818586Non-Executive - Non Independent DirectorNot Applicable16-Oct-1967NoActiveNot Applicable04-Nov-20241000

Committee Disclosures

Entry CompComit122
Date of Appointment
25-Apr-2019
Entry CompComit123
Date of Appointment
22-Oct-2020
Entry CompComit124
Date of Appointment
20-Jul-2022
Entry CompComit14
Date of Appointment
20-Nov-2018
Entry CompComit15
Date of Appointment
22-Oct-2020
Entry CompComit16
Date of Appointment
20-Jul-2022
Entry CompComit41
Date of Appointment
20-Nov-2018
Entry CompComit42
Date of Appointment
22-Oct-2020
Entry CompComit43
Date of Appointment
14-May-2018
Entry CompComit44
Date of Appointment
04-Nov-2024
Entry CompComit68
Date of Appointment
11-Feb-2020
Entry CompComit69
Date of Appointment
11-Feb-2020
Entry CompComit70
Date of Appointment
04-Nov-2024
Entry CompComit95
Date of Appointment
17-May-2021
Entry CompComit96
Date of Appointment
11-Feb-2020
Entry CompComit97
Date of Appointment
04-Nov-2024
Entry CompComit98
Date of Appointment
11-Feb-2020
Entry MainD
Composition And Role Of Risk Management Committee
Yes
Composition Of Audit Committee
Yes
Composition Of Nomination And Remuneration Committee
Yes
Composition Of Stakeholder Relationship Committee
Yes
Composition Of Various Committees Of Board Of Directors
Yes
Disclosure Web Link Of Company At Which Composition Of Various Committees Of Board Of Directors Is Placed
https://glandpharma.com/images/CommitteeofBoardofDirectors.pdf
Memberships In Committees
Yes
Prior Or Omnibus Approval Of Audit Committee For All Related Party Transactions
Yes
Risk Management Committee
Yes
Role Of Audit Committee And Information To Be Reviewed By The Audit Committee
Yes
Role Of Nomination And Remuneration Committee
Yes
Role Of Stakeholders Relationship Committee
Yes
The Committee Members Have Been Made Aware Of Their Powers Role And Responsibilities As Specified In Sebi Regulations2015
Yes
The Composition Of Audit Committee Is In Terms Of Sebi Regulations2015
Yes
The Composition Of The Nomination And Remuneration Committee Is In Terms Of Sebi Regulations2015
Yes
The Composition Of The Risk Management Committee Is In Terms Of Sebi Regulations2015
Yes
The Composition Of The Stakeholders Relationship Committee Committee Is In Terms Of Sebi Regulations2015
Yes
Whether The Audit Committee Has A Regular Chairperson
Yes
Whether The Corporate Social Responsibility Committee Has A Regular Chairperson
Yes
Whether The Nomination And Remuneration Committee Has A Regular Chairperson
Yes
Whether The Risk Management Committee Has A Regular Chairperson
Yes
Whether The Stakeholders Relationship Committee Has A Regular Chairperson
Yes

Audit Committee

Additional Position
Chairperson
Director DIN
00142138
Member Name
Satyanarayana Murthy Chavali
Notes
Mr. Satyanarayana Murthy Chavali was appointed as Chairman of Audit Committee with effect from 22-10-2020.
Position
Non-Executive - Independent Director

Audit Committee

Additional Position
Member
Director DIN
00157299
Member Name
Essaji Goolam Vahanvati
Position
Non-Executive - Independent Director

Audit Committee

Additional Position
Member
Director DIN
00707474
Member Name
UDO JAHANNES VETTER
Position
Non-Executive - Independent Director

Audit Committee

Audit Committee

Corporate Social Responsibility Committee

Additional Position
Chairperson
Director DIN
06900659
Member Name
Srinivas Sadu
Notes
Mr. Srinivas Sadu was appointed as Chairman of Corporate Social Responsibility Committee with effect from 22-10-2020.
Position
Executive Director

Corporate Social Responsibility Committee

Additional Position
Member
Director DIN
00157299
Member Name
Essaji Goolam Vahanvati
Position
Non-Executive - Independent Director

Corporate Social Responsibility Committee

Additional Position
Member
Director DIN
09170927
Member Name
Jia Ai Zhang
Position
Non-Executive - Non Independent Director

Nomination and remuneration committee

Additional Position
Chairperson
Director DIN
00142138
Member Name
Satyanarayana Murthy Chavali
Notes
Mr. Satyanarayana Murthy Chavali was appointed as Chairman of Nomination and Remuneration Committee with effect from 22-10-2020.
Position
Non-Executive - Independent Director

Nomination and remuneration committee

Additional Position
Member
Director DIN
00157299
Member Name
Essaji Goolam Vahanvati
Position
Non-Executive - Independent Director

Nomination and remuneration committee

Additional Position
Member
Director DIN
00707474
Member Name
UDO JAHANNES VETTER
Position
Non-Executive - Independent Director

Nomination and remuneration committee

Additional Position
Member
Director DIN
10818586
Member Name
Wei Huang
Position
Non-Executive - Non Independent Director

Nomination and remuneration committee

Other Committee

Additional Position
Chairperson
Director DIN
00142138
Member Name
Satyanarayana Murthy Chavali
Name Of Other Committee
ESOP Compensation Committee
Position
Non-Executive - Independent Director

Other Committee

Additional Position
Member
Director DIN
00157299
Member Name
Essaji Goolam Vahanvati
Name Of Other Committee
ESOP Compensation Committee
Position
Non-Executive - Independent Director

Other Committee

Additional Position
Member
Director DIN
00707474
Member Name
UDO JAHANNES VETTER
Name Of Other Committee
ESOP Compensation Committee
Position
Non-Executive - Independent Director

Other Committee

Name Of Other Committee
ESOP Compensation Committee

Risk Management Committee

Additional Position
Chairperson
Director DIN
00017806
Member Name
Naina Lal Kidwai
Notes
Ms. Naina Lal Kidwai was appointed as Chairperson of Risk Management Committee with effect from 10-03-2022.
Position
Non-Executive - Independent Director

Risk Management Committee

Additional Position
Member
Director DIN
06900659
Member Name
Srinivas Sadu
Position
Executive Director

Risk Management Committee

Additional Position
Member
Director DIN
09170927
Member Name
Jia Ai Zhang
Position
Non-Executive - Non Independent Director

Risk Management Committee

Additional Position
Member
Director DIN
99999999
Member Name
Ravi Shekar Mitra
Notes
Mr Ravi Shekhar Mitra is not a director, hence DIN is not available
Position
Chief Financial Officer

Risk Management Committee

Risk Management Committee

Stakeholders Relationship Committee

Additional Position
Chairperson
Director DIN
00142138
Member Name
Satyanarayana Murthy Chavali
Position
Non-Executive - Independent Director

Stakeholders Relationship Committee

Additional Position
Member
Director DIN
06900659
Member Name
Srinivas Sadu
Position
Executive Director

Stakeholders Relationship Committee

Additional Position
Member
Director DIN
10727581
Member Name
Wenjie Zhang
Position
Non-Executive - Non Independent Director

Stakeholders Relationship Committee

Entry MainD
Gap Between The Meetings Of The Risk Management Committee
Yes
Meeting Of Audit Committee
Yes
Meeting Of Board Of Directors
Yes
Meeting Of Independent Directors
Yes
Meeting Of Nomination And Remuneration Committee
Yes
Meeting Of Risk Management Committee
Yes
Meeting Of Stakeholders Relationship Committee
Yes
Quorum Of Board Meeting
Yes
Quorum Of Nomination And Remuneration Committee Meeting
Yes
Quorum Of Risk Management Committeemeeting
Yes
The Meetings Of The Board Of Directors And The Above Committees Have Been Conducted In The Manner As Specified In Sebi Regulations2015
Yes
Entry MeetingBOD1
Dates Of Meeting In The Previous Quarter
03-Nov-2025
Number Of Directors Present In Meeting Of Board Of Directors
7
Number Of Independent Directors Attending The Meeting
4
Total Number Of Directors As On Date Of The Meeting
8
Entry MeetingBOD2
Dates Of Meeting If Any In The Relevant Quarter
28-Jan-2026
Maximum Gap Between Any Two Consecutive Meetings
85
Number Of Directors Present In Meeting Of Board Of Directors
7
Number Of Independent Directors Attending The Meeting
3
Total Number Of Directors As On Date Of The Meeting
8
Entry MeetingComit1
Dates Of Meeting Of The Committee In The Previous Quarter
03-Nov-2025
Number Of Director Present In Meeting Of Committee All Directors Including Independent Director
3
Number Of Independent Director Attending Meeting Of Committee
3
Number Of Member Attending Meeting Of Committee
0
Total Number Of Directors As On Date Of The Meeting
3
Entry MeetingComit2
Dates Of Meeting Of The Committee In The Relevant Quarter
28-Jan-2026
Maximum Gap Between Any Two Consecutive Meetings
85
Number Of Director Present In Meeting Of Committee All Directors Including Independent Director
3
Number Of Independent Director Attending Meeting Of Committee
3
Number Of Member Attending Meeting Of Committee
0
Total Number Of Directors As On Date Of The Meeting
3
Entry MeetingComit3
Dates Of Meeting Of The Committee In The Relevant Quarter
03-Mar-2026
Maximum Gap Between Any Two Consecutive Meetings
33
Number Of Director Present In Meeting Of Committee All Directors Including Independent Director
3
Number Of Independent Director Attending Meeting Of Committee
3
Number Of Member Attending Meeting Of Committee
0
Total Number Of Directors As On Date Of The Meeting
3
Entry MeetingComit4
Dates Of Meeting Of The Committee In The Relevant Quarter
03-Mar-2026
Number Of Director Present In Meeting Of Committee All Directors Including Independent Director
3
Number Of Independent Director Attending Meeting Of Committee
3
Number Of Member Attending Meeting Of Committee
0
Total Number Of Directors As On Date Of The Meeting
4
Entry MeetingComit5
Dates Of Meeting Of The Committee In The Relevant Quarter
28-Jan-2026
Number Of Director Present In Meeting Of Committee All Directors Including Independent Director
3
Number Of Independent Director Attending Meeting Of Committee
1
Number Of Member Attending Meeting Of Committee
0
Total Number Of Directors As On Date Of The Meeting
3
Entry MeetingComit6
Dates Of Meeting Of The Committee In The Previous Quarter
16-Oct-2025
Number Of Director Present In Meeting Of Committee All Directors Including Independent Director
3
Number Of Independent Director Attending Meeting Of Committee
1
Number Of Member Attending Meeting Of Committee
1
Total Number Of Directors As On Date Of The Meeting
3
Entry MeetingComit7
Dates Of Meeting Of The Committee In The Relevant Quarter
28-Jan-2026
Maximum Gap Between Any Two Consecutive Meetings
103
Number Of Director Present In Meeting Of Committee All Directors Including Independent Director
1
Number Of Independent Director Attending Meeting Of Committee
0
Number Of Member Attending Meeting Of Committee
1
Total Number Of Directors As On Date Of The Meeting
3
Entry MainD
Contact Information Of The Designated Officials Of The Listed Entity Who Are Responsible For Assisting And Handling Investor Grievances
Yes
Disclosure Web Link Of Company At Which Contact Information Of The Designated Officials Of The Listed Entity Who Are Responsible For Assisting And Handling Investor Grievances Is Placed
https://glandpharma.com/investors/investors-contacts
Disclosure Web Link Of Company At Which Email Address For Grievance Redressal And Other Relevant Details Is Placed
https://glandpharma.com/investors/shareholder-information#grievance-redressal
Email Address For Grievance Redressal And Other Relevant Details
Yes
No Of Investor Complaints Disposed Off During The Period
0
No Of Investor Complaints During The Period
0
No Of Investor Complaints Received During The Period
0
Whether Part B Of Annexure I Of The SEBI Circular Dated31December2024Related To Investor Grievance Redressal Report Is Applicable To The Entity
Yes
Entry MainI
No Of Investor Complaints
0
Entry PY_I
No Of Investor Complaints
0
Composition Of Board Of Directors Of Unlisted Material Subsidiary
Yes
Reason For Part C Of Annexure I Of The SEBI Circular Dated31December2024Related To Disclosure Of Acquisition Of Shares Or Voting Rights In Unlisted Companies Is Not Applicable To The Entity
Not applicable for this quarter
Whether Part C Of Annexure I Of The SEBI Circular Dated31December2024Related To Disclosure Of Acquisition Of Shares Or Voting Rights In Unlisted Companies Is Applicable To The Entity
No
Reason For Part E Of Annexure I Of The SEBI Circular Dated31December2024Related To Disclosure Of Updates To Ongoing Tax Litigations Or Disputes Is Not Applicable To The Entity
Not applicable during this quarter
Whether Part E Of Annexure I Of The SEBI Circular Dated31December2024Related To Disclosure Of Updates To Ongoing Tax Litigations Or Disputes Is Applicable To The Entity
No
Reason For Part D Of Annexure I Of The SEBI Circular Dated31December2024Related To Disclosure Of Imposition Of Fine Or Penalty Is Not Applicable To The Entity
Not applicable during this quarter
Whether Part D Of Annexure I Of The SEBI Circular Dated31December2024Related To Disclosure Of Imposition Of Fine Or Penalty Is Applicable To The Entity
No